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Abstract
Chronic relapsing-remitting experimental allergic encephalo-
myelitis (EAE) was induced in cynomolgus monkeys by a sin-
gle immunization with a homogenate of human brain white
matter (BH) in adjuvant. Proliferative T lymphocyte responses
to BH, to myelin basic protein (MBP), but not to proteolipid
protein, were detected in peripheral blood mononuclear cells
(PBMC) of all animals and persisted until their death or, in
surviving animals, for > 10 mo postimmunization. Responses
of higher magnitude tended to be associated with fatal, com-
pared with nonfatal, episodes ofclinical EAE. The frequency of
MBP-reactive T cells inPBMC ofanimals with acute EAE was
quantitated with a soft agar colony system; the ratio of T cells
that proliferated specifically to MBP was estimated at between
5 and 20 per 10' PBMC. A similar frequency of peptide-speci-
fic T cells was estimated from PBMC of monkeys immunized
with a synthetic 14-mer peptide corresponding to a region near
the carboxy terminus of MBP. Thus, autoantigen-reactive T
cells can be detected in the circulation throughout the course of
chronic EAE, are predictive of disease severity, and occur at a
frequency similar to that estimated to be present in humans
with multiple sclerosis. (J. Clin. Invest. 1992. 90:399404.)
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Introduction
Experimental allergic encephalomyelitis (EAE)1 is an autoim-
mune disease ofthe central nervous system (CNS) that is me-
diated, in most species studied, by T cells reactive with myelin
basic protein (MBP) ( 1, 2). Because of pathologic similarities
between EAE and the human demyelinating disease, multiple
sclerosis (MS), EAE has long served as a model system for
testing of potential new therapies for MS patients. Trials in
EAE have for the most part relied upon clinical end points
(e.g., severity ofparalysis) in the assessment ofdisease severity
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1. Abbreviations used in this paper: BH, human brain white matter
homogenate; CFA, complete Freund's adjuvant; CSF, cerebrospinal
fluid; EAE, experimental allergic encephalomyelitis; MBP, myelin ba-
sic protein; MS, multiple sclerosis; PLP, phospholipid protein.
(3). Other proposed markers ofthe EAE process, for example,
the quantitation of CNS inflammation (4-6) or the measure-
ment of various nonspecific immune parameters (7, 8), have
not gained widespread use. Some markers correlate poorly with
the clinical illness score (4-6) and may require sacrifice of the
subjects. These limitations are particularly evident in studies of
chronic relapsing-remitting EAE, the most appropriate model
system for human MS (9).
The current experiments were designed to assess the hy-
pothesis that antigen-specific immune responses measured in
peripheral blood provide an informative marker of the EAE
process. Antigen reactivity from lymph node and splenic T
cells has been studied extensively in EAE, whereas little is
known ofthe T cell response by peripheral blood mononuclear
cells (PBMC). By contrast, in humans with MS, PBMC re-
sponses have been characterized in detail. In particular, recent
studies indicate that some PBMC responses to MBP are char-
acteristic of MS ( 10-14); for example, a high frequency of
reactive cells (12) or the preferential recognition of certain
MBP epitopes (14) may be present.
Chronic relapsing-remitting EAE has been described in
nonhuman primates ( 15-19), and these species are particu-
larly attractive as MS models because oftheir close phylogeneic
relationship to humans, their large size, and their outbred char-
acteristics. We describe in this report an improved model of
EAE in the cynomolgus monkey. Relapsing-remitting disease
can be induced in some animals with only one injection and in
the absence of corticosteroid treatment ( 16, 18). We demon-
strate that PBMC T cell responses correlate with disease sever-
ity. Furthermore, we find that the frequency ofPBMC reactive
to MBP in EAE is similar to that described in some patients
with MS ( 12). Thus, in a chronic organ-specific autoimmune
disease, PBMC responses reflect disease severity, and their mea-
surement provides a quantitative marker ofthe underlying au-
toimmune state.
Methods
Induction ofEAE in Macaca fascicularis. Macaca fascicularis were
maintained in the New England Regional Primate Research Center
colonies. The animals used in this study were cared for in accordance
with the guidelines ofthe Committee on Animals ofthe Harvard Medi-
cal School and those of the Committee on Care and Use ofLaboratory
Animals of the Institute of Laboratory Animal Resources, National
Research Council. A maximum of 10 ml ofblood every other week or 1
ml of cerebrospinal fluid (CSF) obtained by lumbar puncture on two
occasions was taken from each animal.
A total of 18 animals were immunized with 200 mg of fresh-frozen
postmortem human brain white matter homogenate (BH) emulsified
with complete Freund's adjuvant (CFA) containing killed Mycobacte-
rium tuberculosis (H37 Ra strain, 3 mg/ml). Intradermal injections
(total volume of 0.5 ml per animal) were divided in four sites on the
dorsal axillary and inguinal region. Three ofthese animals were preim-
munized with a synthetic 14-mer peptide corresponding to a region
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near the carboxyl terminus (e.g., amino acids 156-169) of MBP, in
either CFA/H37Ra or incomplete Freund's adjuvant supplemented
with muramyl dipeptide (2 Ag); EAE was induced in these animals by
immunization with BH/CFA-H37Ra.
Many animals developed injection site ulcerations 2-5 wk postim-
munization. In these cases, cephalexin (20 mg/kg twice daily for 10 d)
was administered intramuscularly to prevent secondary infection.
Clinical scoring ofEAE. Animals were observed daily for signs of
disease. The following scoring system was employed to categorize the
disease state:
Score Clinical state
0 Normal neurological exam
I Lethargy, anorexia, weight loss
2 Ataxia, tremor
3 Blindness, paraplegia, hemiplegia
4 Quadriplegia, quadriparesis
5 Moribund
Proliferation studies. PBMC were prepared from heparinized ve-
nous blood within 3 h of venipuncture by density gradient centrifuga-
tion using dextran diatrizoate (d 1,080). PBMC (2 X 01 per well) were
cultured in a total volume of200 ul in round-bottom microtiter plates
(Falcon Plastics Oxnard, CA) in culture medium consisting ofRPMI
1640 supplemented with 10% Controlled Processed Serum Replace-
ment-2 (Sigma Pharmaceuticals, St. Louis, MO), 100 mM L-gluta-
mine (Gibco Laboratories, Grand Island, NY), 25 mM Hepes buffer
(Sigma), and 0.1% penicillin-streptomycin (Gibco). To some wells the
following antigens (final concentration) were added: (a) human MBP
(50 ug/ml) prepared by the method of Deibler et al. (20); (b) human
phospholipid protein (PLP) apoprotein (10 ;gf/ml), prepared by the
method of Lees and Sakur (21 ); (c) human BH, 0.1%, sonicated and
irradiated; (d) a synthetic 14-mer peptide corresponding to the region
156-169 (FKLGGRDSRGGSPM) of human MBP (100 ug/ml); (e)
concanavalin A (ConA) (4 Mg/ml) (Sigma); (I) phytohemagglutinin
(PHA; 4 ,ug/ml) (Sigma). After 5 d of incubation, [3H]thymidine ( 1
MCi/ml) was added for another 16 h, cells were harvested, and thymi-
dine incorporation measured in a scintillation counter. Proliferative
responses were expressed as stimulation indexes, defined as the stimu-
lated culture counts per minute per unstimulated culture counts per
minute in triplicate wells.
Soft agar colony quantitation of antigen-reactive T lymphocytes.
This method was modified from Sredni et al. (22). PBMC (2 X 106/
ml) were cultured for 3 d in medium supplemented with 10% human
AB serum in the presence or absence ofMBP (50 ug/ml). Cells were
then pelleted and resuspended in medium supplemented with 20% hu-
man AB serum, agar was added (0.32% final concentration) in flat
bottom wells, and the suspension was overlaid on a second layer ofagar
(0.5%) containing medium supplemented with 20% human AB serum
and 50 ug/ml MBP. The number of colonies were counted under
blinded conditions between 6 and 11 d later using an inverted micro-
scope. The number ofMBP-specific colonies was estimated by subtrac-
tion ofthe number ofcolonies in the MBP from those in control wells.
Results
ClinicalEAE in cynomolgus monkeys. Signs ofEAE developed
in all 15 animals immunized with BH. The clinical course took
the form ofan acute progressive illness leading to death within
6-12 d (n =. 11 ) or to complete recovery followed by the devel-
opment of a relapsing-remitting chronic disease (n = 4). The
time of onset ofthe initial illness ranged from day 17 to day 55
after immunization. Attacks ofEAE accompanied by a clinical
score of 4 or greater were invariably associated with a fatal
outcome. No difference in the degree ofCSF pleocytosis differ-
entiated fatal from nonfatal attacks (Table I).
In the four animals that survived the initial attack of EAE,
late relapses, numbering 1-6, occurred in all cases. These re-
lapses resulted in death in two animals; two late survivors
(> 10 mo postimmunization) remain. One long-term survivor
had a single relapse of 14 d duration followed by complete
clinical recovery. One animal developed five relapses of vari-
able duration followed by complete recovery. One animal be-
came permanently blind 272 d postimmunization. Most ani-
mals achieved complete clinical neurologic recovery after re-
lapses that did not result in death. Fig. 1 summarizes the
clinical characteristics ofEAE in six representative animals.
Several clinical syndromes seen in these monkeys resem-
bled those present in human demyelinating disorders. These
included bilateral optic neuritis with marked visual disability
but preserved strength and coordination; pure ataxia, acute
vomiting, and instability of gait; and progressive myelopathy
evolving over several days.
Sensitization to EAE by MBP 156-169. Three animals
were preimmunized with a synthetic peptide corresponding to
the 156-169 carboxy-terminal region ofMBP. No signs ofEAE
were noted during a 14-mo period of observation. These ani-
mals were then immunized with BH/CFA. As shown in Fig. 2,
clinical signs developed in this group between 9 and 11 d after
immunization, compared to with onset no earlier than day 17
in the animals not preimmunized in this manner. The clinical
course in peptide preimmunized animals was otherwise identi-
cal to that seen in nonpreimmunized animals: either a progres-
sive syndrome leading to death (n = 2) or a relapsing-remitting
course(n= 1).
Proliferative responses to brain antigens. PBMC prolifera-
tive responses to BH, MBP, PLP, and mitogen (Con A or
PHA) were assessed prospectively. As illustrated in Fig. 1 for
six representative animals, proliferative responses to BH and to
MBP were typically absent before immunization and in the
early postimmunization period, but became positive at the on-
set of clinical signs ofEAE. In animals with chronic, relapsing-
remitting EAE (Fig. 1, lowerpanels), positive PBMC responses
to BH and MBP, once present, persisted for the duration of
study, up to 10 mo postimmunization. Stimulation indexes in
chronic EAE were low, generally < 10 times background val-
ues. In both acute and chronic EAE, proliferative responses to
PLP were generally low or undetectable, although an occa-
sional animal did mount a detectible PLP-specific response
(Fig. 1, bottom right).
Table I. Stimulation Index Correlations
PBMC stimulation index
BH MBP CSF
cells/mm'
Nonfatal attacks 6.3±2.1 5.7±1.5 307±122
(n= 15) (n= 16) (n=7)
Fatal attacks 13.0±3.6 8.2±3.4 352±158
(n = 8)* (n = 8) (n = 7)
400 Massacesi et al.
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Figure 2. The clinical course of EAE in three cynomolgus monkeys
immunized with the 14-mer MBP peptide before receiving a second
immunization with BH. Preimmunization was accomplished using
either CFA (middle panel) or Freund's adjuvant supplemented with
muramyl dipeptide (top and bottom panels) as adjuvant. Clinical
signs ofEAE were present in all animals between 9 and 11 d postim-
munization (PI). For each animal, the clinical course (y-axis) is il-
lustrated for the time period after immunization with white matter
homogenate (x-axis).
Table I summarizes PBMC responses to BH and MBP in
relation to the onset of fatal and nonfatal attacks of EAE. The
magnitude ofthe proliferative response to BH and MBP varied
widely between animals. Immunization was associated with a
fourfold increase in mitogen responsiveness and with the devel-
opment of antigen-specific PBMC proliferative responses. A
general correlation was observed between the magnitude ofthe
response to BH and the severity of individual attacks: higher
stimulation indexes tended to be associated with fatal outcome
(Table I). No differences in the proliferative response to mito-
gens differentiated fatal from nonfatal attacks (not shown).
Quantitation of the circulating T cell response. In six ani-
mals immunized with BH/CFA, the number ofT cells specific
to MBP were enumerated from peripheral blood by use of a
soft agar colony system. The frequency ofMBP-specific T cells
could be estimated at between 5 and 20 per 106 PBMC. As
shown in Fig. 3, the number ofMBP colonies and the kinetics
of their appearance postimmunization in three individual ani-
mals correlated with the magnitude and kinetics ofthe prolifer-
ative response of whole PBMC to MBP.
In the three animals preimmunized with the MBP 156-169
peptide, peptide-specific colonies, enumerated on day 55 pos-
timmunization, were estimated at 1, 6, and 9 per 106 PBMC,
respectively. PBMC proliferative responses to this peptide were
generally low or undetectible, both in peptide-preimmunized
animals (data not shown) and also in animals immunized only
with BH/CFA (for example, Fig. 1, top right).
Discussion
The current report represents the first study of circulating anti-
gen-specific T cells in relapsing-remitting EAE. The large size
ofthe animals and the chronic course provided the opportunity
for serial phlebotomy and measurement of antigen reactivity
during the course ofthe disease. Specific proliferative responses
to BH and to MBP were present in all animals at the onset of
clinical signs ofEAE, and these responses persisted in surviving
animals for the duration of study. Strong proliferative re-
sponses were associated with fatal attacks in most cases. Re-
sponses to PLP, a myelin protein capable of inducing EAE in
some species (23), were generally undetectable or of lower
magnitude than were those to BH or MBP.
In earlier studies of acute EAE in various species, PBMC
responses to MBP were detected in some (24-27) but not in
other (28) models. In the guinea pig, this response was tran-
sient and present only during the acute phase of disease (26).
Current primate data, by contrast, indicate that antigen-reac-
tive PBMC were present in all survivors ofacute EAE, even for
periods up to 10 mo postimmunization and long after the dis-
solution of a visible antigen depot. The persistence of these
circulating cells may have contributed to the high relapse rate
that occurred in this species.
A soft agar method for the enumeration ofantigen-reactive
T cells permitted an estimate of the frequency of circulating
MBP-reactive cells to be made. In acute EAE, between 5 and 20
per 106 PBMC proliferated specifically to MBP. Unpublished
data from our laboratory also indicate that a lower frequency of
MBP-reactive T cells, estimated at 1 per 106 PBMC, are present
in clinically stable animals with chronic EAE studied 6-18 mo
postimmunization. The true clonal frequency may be higher
than these estimates, assuming limited sensitivity of the assay
(particularly with respect to the CD8+ repertoire). On the
other hand, only a fraction ofT cells that proliferate to MBP in
vitro are likely to be encephalitogenic in vivo (29). These con-
siderations notwithstanding, it appears that, even during the
course of acute fulminant EAE, few antigen-reactive cells are
present in proliferation assays that typically employ 105 to 106
PBMC per well.
In humans with MS, small increases in PBMC responses to
MBP are reported to distinguish patients from controls (10-
14). One recent estimate indicated that between 27 and 52 per
106 PBMC were MBP-reactive as measured by MBP-induced
402 Massacesi et al.
I
2
I
T
O MBP Stimulation Index
MBP Colonies/ I cf PBMC
Dws P/
Figure 3. Correlation be-
tween the PBMC stimulation
index and the frequency of
MBP-specific T-cell colonies.
Data from three immunized
animals are shown. The
stimulation index, or the
number of colonies detected
per 106 PMBC, is displayed
on the y-axis and the day
postimmunization is shown
on the x-axis. The shaded
area represents the onset of
clinical signs ofEAE. See text
for details.
interferon-y secretion (12). A lower estimate (1-5 per 106
PBMC) was suggested in a second study ofMBP precursors in
PBMC ofMS patients (H. Offner and A. Vandenbar, personal
communication). Thus, similar frequencies of circulating
MBP-reactive cells may be present in both MS and EAE.
In the related species Rhesus (Macaca mulatta), EAE was
induced by immunization with peptides corresponding to the
carboxy-terminal region of MBP (30-33). In cynomolgus
monkeys, we found that signs ofEAE did not develop when a
similar immunization regimen was employed, but that a mark-
edly precocious onset ofEAE followed subsequent immuniza-
tion with BH/CFA-H37Ra. This suggests that peptide immuni-
zation may have sensitized the animals to EAE. It is surprising
that the same region ofMBP may play a role in inducing EAE
in most if not all individuals belonging to two distinct (al-
though closely related) primate species. In inbred rodents, the
encephalitogenic T cell response to MBP has been shown to be
strain and species specific, and to recognize restricted regions of
MBP in the generation of an encephalitogenic response (re-
viewed in reference 34). In H-2U mice (B10.PL and PL/J), for
example, the amino terminus ofMBP is immunodominant for
EAE, whereas in H-2' mice (SJL) the 89-101 region is domi-
nant. In nonhuman primates extensive polymorphism of ma-
jor histocompatibility complex (MHC) gene products is pres-
ent (35, 36) that might contribute to diversity in the response
to MBP. Heterozygosity for MHC haplotypes in many individ-
uals, coupled with additional MHC diversity resulting from
interisotypy or transcomplementation, might broaden the po-
tential for generation of T cell responses against multiple epi-
topes of a given antigen. In marmoset primates, for example,
we have found that T-cell lines responding to different regions
of MBP can mediate passive transfer EAE (Massacesi et al.,
manuscript in preparation), and in MS patients no single re-
gion ofMBP has been identified as immunodominant ( 14, 37,
38). In macaques, sensitization to EAE by the carboxyterminal
region ofMBP suggests that effective presentation of epitopes
within this peptide to T cells is mediated by a variety of differ-
ent MHC haplotypes.
In conclusion, relapsing-remitting EAE in cynomolgus
monkeys is characterized by circulating T cell responses to
white matter antigens that persist over long periods oftime and
that broadly mirror the clinical illness. Furthermore, our data
indicate that a chronic inflammatory disease in primates may
result from relatively small increases in the circulating pool of
cells responding to the target antigen. In rodents, intravenous
passive transfer ofas few as 30,000 cloned MBP-reactive T cells
can produce EAE (39), demonstrating the remarkable effi-
ciency ofsome encephalitogenic T cell populations to mediate
disease. Serial assessment of autoantigen-reactive T cells from
peripheral blood is thus a quantifiable immunologic marker of
the disease process that can be easily applied to trials oftherapy
in EAE, and similar strategies may prove useful for monitoring
of humans with MS or other T cell-mediated inflammatory
diseases.
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